General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal’s scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the International Institute of Anticancer Research and is available online with Stanford University HighWire Press: For more information please visit our website www.cgp.iiarjournals.org.

Editorial Office
International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389. E-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

A Selection of Recent Papers


Crucial and Novel Cancer Drivers in a Mouse Model of Triple-Negative Breast Cancer. J.P.S. JOHNSON, P. KUMAR, M. KOULNIS, M. PATEL, K. SIMIN (Worcester, MA; Bethesda, MD; Scranton, PA; New York, NY, USA; Singapore, Singapore)

Cilia Gene Expression Patterns in Cancer. M. SHPAK, M.M. GOLDBERG, M.C. COWPERTHW AITE (Austin TX, USA)

MicroRNA-150 Is Up-regulated in Extranodal Marginal Zone Lymphoma of MALT Type. N. GEBAUER, J. KUBA, A. SENFT, A. SCHILLERT, V. BERNARD, C. THORN (Lübeck, Germany)


Fucoidan-dependent Increased Membrane Component in HepG2: Effect of Fucoidan Is Not Due to Gene Expression. K. HAYAKAWA, T. NAGAMINE (Tokyo; Gunma, Japan)


A Novel Transmembrane Glycoprotein Cancer Biomarker Present in the X Chromosome. A.P. DELGADO, S. HAMID, P. BRANDAO, R. NARAYANAN (Boca Raton, FL, USA)

Rho Kinase Proteins Regulate Global miRNA Expression in Endothelial Cells. J.M. STILES, V. KURISSETTY, D.C. MITCHELL, B.A. BRYAN (El Paso, TX, USA)

Gene Expression Profiling of Circulating Natural Killer Cells in Head and Neck Squamous Cell Carcinoma. A. BOTTCHER, J. OSTWALD, D. KOCZAN, R. KNECHT, B. KRAMP, S. DOMMERICH (Hamburg; Rostock; Berlin, Germany)


Isolation of Stem Cells Using Spheroids from Fresh Surgical Specimen: An Analytic Mini-review. I. AVITAL, A. STOJADINOVIC, H. WANG, C. MANNION, W.C.S. CHO, J. WANG, Y.G. MAN (Richmond, VA; Hackensack, NJ; Washington, DC, USA; Hangzhou, China; Hong Kong, Hong Kong)

Instructions to Authors 2014

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):
1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Delinasios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2014 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
Subscription Order Form 2014

☐ Please enter a Subscription to ANTICANCER RESEARCH Volume 34 (2014).
  Annual subscription rates (2013): Institutional, Euro 1,650.00 print or online; Personal, Euro 780.00 print or online;
  Prices include rapid delivery and insurance.

☐ Please send me the following previous volumes (1-33) at 50% discount on the above rates.
☐ Payment is enclosed. ☐ Please invoice.

☐ Checks should be made payable to Delinasios G.J. & CO G.P. (Athens, Greece)

☒ Please send me information about the International Institute of Anticancer Research (IIAR).

Name and Address: ..........................................................................................................................................................
..................................................................................................................................................................................................
..................................................................................................................................................................................................
Tel: ...............................................................................................................................................................................................
Fax: ....................................................................................................................................................................................... e-mail: ..............................................................................................................................................................................
Signature:........................................................................................................................................................................... Date: ........................................................................

Please send this order to ANTICANCER RESEARCH, Subscription Office, IIAR, 1st km Kapandritiou-Kalamou Rd.,
Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel & Fax: +30-22950-53389, e-mail: subscriptions@iiar-anticancer.org

Special 2014 Offers to Authors of ANTICANCER RESEARCH

These offers are open to all authors of articles published in Anticancer Research from 1981-2014 on a basis of priority and availability.
Effective from January to December 2014.

- Included in Pubmed, Current Contents and all abstracting and indexing services
- Online with Stanford University HighWire Press
- Open access articles

Please complete and send this order form to:
ANTICANCER RESEARCH, International Institute of Anticancer Research,
1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece.

Special Subscription Order Form 2014

☐ I am one of the authors of the article published in Anticancer Research Vol. ....... pp. ........., year ........

☐ Please enter my personal subscription to Anticancer Research 2014 (Volume 34) at the special Author’s rate of Euro 390.00 (print or online).

☐ Please send me previous Volume No(s) ............ at Euro 195.00 (print) per volume.

☐ Please enter my personal combined 2014 subscription to Anticancer Research (Volume 34) and IN VIVO (Volume 28) at Euro 560.00 (print or online).

☐ My payment is enclosed.

☐ Please send me an invoice.

Prices include rapid delivery and insurance. Checks should be made payable to Delinasios G.J. & CO G.P. (Athens, Greece).

Name and address: ..........................................................................................................................................................
..................................................................................................................................................................................................
..................................................................................................................................................................................................
Tel-Fax: ....................................................................................................................................................................................... e-mail: ..............................................................................................................................................................................
Date and signature: ......................................................................................................................................................................................
Impact of PSA Levels on Second-round Screening for the Development of Prostate Cancer in Men with Low Baseline PSA Levels (≤2.0 mg/ml). Y. KITAGAWA, K. SAWADA, S. URATA, K. IZUMI, S. UENO, Y. KADONO, H. KONAKA, A. MIZOKAMI, M. NAMIKI (Ishikawa, Japan) .......................................................... 6739

Fatal Stimulation of Acute Myeloid Leukemia Blasts by Pegfilgrastim. C. DUVAL, S. BOUCHER, J.-C. MOULIN, B. GOURIEUX, L. MAUVIEUX, D. LEVEQUE, R. HERBRECHT (Strasbourg, France) .......... 6747

Usefulness of MRI of Microcalcification Lesions to Determine the Indication for Stereotactic Mammothome Biopsy. M. KIKUCHI, H. TANINO, Y. KOSAKA, N. SENGOKU, K. YAMASHITA, N. MINATANI, H. NISHIMIYA, M. WARAYA, H. KATOH, T. ENOMOTO, S. KAJITA, R. WOODHAMS, M. WATANABE (Kanagawa, Japan) ........................................................................................................................ 6749

Concurrent Chemoradiotherapy with or without Induction Chemotherapy versus Chemotherapy Alone in Patients with Locally Advanced Pancreatic Cancer. W.-K. HUANG, Y.-C. KUO, N.-M. TSANG, H.-C. HSU, W.-C. SHEN, W.-C. CHOU, T.-S. YANG, J.-S. CHEN (Taoyuan, Taiwan, ROC) ............... 6755

Predicting Overall Survival in Patients with Brain Metastases from Esophageal Cancer. D. RADES, L. DZIGGEL, T. BARTSCHT, J. GLEIMROTH (Lübeck, Germany) .............................................................. 6763

Preoperative Treatment with Capecitabine, Cetuximab and Radiotherapy for Primary Locally Advanced Rectal Cancer – A Phase II Clinical Trial. W. EISTERER, A. DE VRIES, D. ÖFNER, H. RABL, R. KOPLMÜLLER, R. GREIL, J. TSCHMELITSCH, R. SCHMID, K. KAPP, P. LUKAS, F. SEDLMAYER, G. HÖFLER, M. GNANT, J. THALER on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCDS) (Innsbruck; Feldkirch; Salzburg; Leoben; Wels; Sankt Veit an der Glan; Vienna; Graz, Austria) .................................................. 6767

Safety and Efficacy of Radiofrequency Ablation with Aflibercept and FOLFIRI in a Patient with Metastatic Colorectal Cancer. A. AGARWAL, K.P. DALY, H. BUTLER-BOWEN, M.W. SAIF (Boston, MA, USA) .... 6775

Value of Uroplakin III in Distinguishing Variants of Primary Bladder Urothelial Carcinoma from Malignancy Metastatic to the Urinary Bladder. K. KLOPFER, B. DELAHUNT, M. ADAMSON, H. SAMARATUNGA (Brisbane, Queensland, Australia; Wellington, New Zealand) ........................................... 6779

Hepatocellular Carcinoma Invading Portal Venous System in Cirrhosis: Long-term Results of Percutaneous Radiofrequency Ablation of both the Nodule and Portal Vein Tumor Thrombus. A Case Control Study. A. GIORGIO, G. CALISTI, L. MONTESARCHIO, U. SCOGRAMIGLIO, P. MATTEUCCI, C. COPPOLA, F. SCARANO, F. AMENDOLA, V. GIORGIO (Naples; Rome; Gragnano; Salerno, Italy; London, UK) .......... 6785

Multi-targeted Approach to Cancer Treatment: An International Translational Cancer Research Symposium. K. MEHTA, V. GANDHI, S. PATHAK, B.B. AGGARWAL, R.K. GROVER (Houston, TX, USA; Delhi, India)....................................................... 6791

Liver Resectability of Advanced Liver-limited Colorectal Liver Metastases Following mFOLFOX6 with Bevacizumab (KSCC0802 Study). T. BEPPU, Y. EMI, S. TÖKUNAGA, E. OKI, K. SHIRABE, S. UENO, M. KURAMOTO, A. KABASHIMA, I. TAKAHASHI, H. SAMURA, S. EGUCHI, Y. AKAGI, S. NATSUGOE, Y. OGATA, Y. KAKEJI, H. BABA, Y. MAEHARA, KYUSHU STUDY GROUP OF CLINICAL CANCER (KSCC) (Kumamoto; Fukuoka; Kagoshima; Ehime; Okayama; Nagasaki; Kurume; Kobe, Japan) 

Measurement of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Cytokeratin-19 Fragment and Matrix Metalloproteinase-7 for Detecting Cholangiocarcinoma: A Preliminary Case-Control Study. F. LUMACHI, G. LO RE, R. TOZZOLI, F. D’AURIZIO, F. FACOMER, G.B. CHIARA, S.M.M. BASSO (Padova; Pordenone, Italy)


Radiotherapy for Stage I/II Follicular Lymphoma (FL): Is it Time for A Re-appraisal? P. MONDELLO, N. STEINER, I. WASLE, V. PITINI, M. MIAN (Messina; Bolzano, Italy; Innsbruck; Feldkirch, Austria)

Circulating Tumor Cells as a Biomarker Predictive of Sensitivity to Docetaxel Chemotherapy in Patients with Castration-resistant Prostate Cancer. T. OKEGAWA, N. ITAYA, H. HARAI, M. TAMBO, K. NUTAHARA (Tokyo, Japan)


Vincristine-induced Blindness: A Case Report and Review of Literature. S. ADHIKARI, R.M. DONGOL, Y. HEWETT, B.K. SHAH (Leawiston, ID, USA)

Relevance of Pelvic and Para-aortic Node Metastases in Early-stage Ovarian Cancer. C. BACHMANN, B. KRÄMER, S.Y. BRUCKER, A. STÄBLER, F. FEND, D. WALLWIENER, E.M. GRISCHKE, R. ROTHMUND (Tübingen, Germany)
Development and Pre-clinical Evaluation of New $^{68}$Ga-NOTA-folate Conjugates for PET Imaging of Folate Receptor-positive Tumors. I. ALJAMMAZ, B. AL-OTAIBI, N. AL-HOKBANY, S. AMER, S. OKARVI (Riyadh, Kingdom of Saudi Arabia) ................................................................. 6547

A B-myb – DREAM Complex Is Not Critical to Regulate the G$_2$/M Genes in HPV-transformed Cell Lines. N. NOR RASHID, R. YUSOF, R.J. WATSON (London; Birmingham, UK; Kuala Lumpur, Malaysia) .... 6557

Sodium Valproate, a Histone Deacetylase Inhibitor, Enhances the Efficacy of Vinorelbine-Cisplatin-based Chemoradiation in Non-small Cell Lung Cancer Cells. V. GAVRILOV, K. LAVRENKO, S. ARIAD, S. SHANY (Beer-Sheva, Israel) ................................................................. 6565

Cytotoxic and Anti-metastatic Activities of Phenolic Compounds from *Dendrobium ellipsophyllum*. K. TANAGORNMEATAR, C. CHAOTHAM, B. SRITULARAK, K. LIKHITWITAYAWUID, P. CHANVORACHOTE (Bangkok, Thailand) ................................................................. 6573

Clinical Studies

End-of-Life Pain Medication among Cancer Patients in Hospice Settings. L. KOIVU, T. PÖLÖNEN, T. STORMI, E. SALMINEN (Turku, Finland) ........................................................................................................ 6581


Significance of Self-reported Symptoms as Part of Follow-up Routines in Patients Treated for Oral Squamous Cell Carcinoma. U. ZÄTTERSTRÖM, M, BOYSEN, J.F. EVENSEN (Oslo, Norway) ........ 6593

Role of Interferon-alpha in Patients with Neuroendocrine Tumors: A Retrospective Study. E. MIRVIS, D. MANDAIR, J. GARCIA-HERNANDEZ, M. MOHMADUHESH, C. TOUMPANAKIS, M. CAPLIN (London, UK) ................................................................................................................................ 6601

Efficacy of *Nab*-Paclitaxel Does Not Seem to Be Associated with SPARC Expression in Metastatic Breast Cancer. A. SCHNEEWEISS, J. SEITZ, K. SMETANAY, F. SCHUETZ, D. JAEGGER, A. BACHINGER, M. ZORN, H.-P. SINN, F. MARMÉ (Heidelberg; Leverkusen, Germany) ......................................................... 6609

Clinical Significance of Pathological Complete Response in Patients with Metastatic Gastrointestinal Stromal Tumors after Imatinib Mesylate Treatment – Lessons Learned. C.-T. CHENG, C.-Y. TSAI, C.-N. YEH, K.-C. CHIANG, Y.-Y. CHEN, S.-Y. WANG, T.-W. CHEN, J.-H. TSENG, S.-M. JUNG, T.-C. CHEN, T.-S. YEH (Taoyuan; Kaohsiung, Taiwan, ROC) ......................................................... 6617

Botulinum Toxin for Salivary Disorders in the Treatment of Head and Neck Cancer. A. STEFFEN, K. HASSELBACHER, S. HEINRICHS, B. WOLLENBERG (Lübeck, Germany) ......................................................... 6627


Survival After Palliative Radiotherapy in Geriatric Cancer Patients. C. NIEDER, K. ANGELO, E. HAUKLAND, A. PAWINSKI (Bodø; Tromsø, Norway) .................................................................................................................. 6641

Relevance of Calcitonin Cut-off in the Follow-up of Medullary Thyroid Carcinoma for Conventional Imaging and 18-Fluorine-Fluorodihydroxyphenylalanine PET. A. SESTI, M. MAYERHOEFER, M. WEBER, P. ANNER, W. WADSAK, R. DUDCZAK, A. HAUG, G. KARANIKAS (Vienna, Austria)......... 6647

Contents continued on the preceding page
BH3 Mimetics Inhibit Growth of Chondrosarcoma – A Novel Targeted-therapy for Candidate Models. T. MORII, K. OHTSUUKA, H. OHNISHI, K. MOCHIZUKI, A. YOSHIYAMA, T. AOYAGI, F.J. HORNICEK, S. ICHIMURA (Tokyo, Japan; Boston, MA, USA) .......................................................... 6423

Indoleamine-2,3-dioxygenase in an Immunotherapy Model for Ewing Sarcoma. D. MAX, C.D. KÜHNÖL, S. BURDACH, L. NIU, M.S. STAEGE, J.L. FÖLL (Halle; Munich; Regensburg, Germany; Atlanta, GA, USA) .......................................................................................................................... 6431

Surrounding Cells Affect the Gene Expression Pattern of Human Betadefensins in Squamous Cell Carcinoma In Vitro. S. KIDA-TAKAOKA, T. YAMAII, N. MIZUKAWA, J. MURAKAMI, S. IIDA (Okayama, Japan) ......................................................................................................................... 6443

The Combination of Nuclear Factor Kappa B, Cyclo-oxygenase-2 and Vascular Endothelial Growth Factor Expression Predicts Poor Prognosis in Stage II and III Colorectal Cancer. N.K. KIM, J.K. PARK, E. SHIN, Y.W. KIM (Seoul; Seongnam; Wonju, Republic of Korea) ............................................................................................................... 6451

HDAC Inhibitor-loaded Bone Cement for Advanced Local Treatment of Osteosarcoma and Chondrosarcoma. M. TONAK, M. BECKER, C. GRAF, L. ECKHARD, M. THEOBALD, P.M. ROMMENS, T.C. WEHLER, D. PROSCHEK (Mainz; Mannheim; Homburg; Germany) ................................................................................................................. 6459

Antitumor Activity of Acriflavine in Lung Adenocarcinoma Cell Line A549. C.-J. LEE, C.-H. YUE, Y.-J. LIN, Y.-Y. LIN, S.-H. KAO, J.-Y. LIU, Y.-H. CHEN (Taichung, Taiwan, ROC) .............................................................................................................. 6467


Effect of Neoadjuvant Chemoradiation on Tumor-infiltrating/associated Lymphocytes in Locally Advanced Rectal Cancers. S.H. LIM, W. CHUA, C. CHENG, J. DESCALLAR, W. NG, M. SOLOMON, L. BOKEY, K. WONG, M.T. LEE, P. DE SOUZA, J.-S. SHIN, C.S. LEE (Liverpool; Kensington; Camperdown; Sydney; Campbelltown, Australia) ............................................................................................................. 6505

Reduced Expression of Growth and Differentiation Factor-9 (GDF9) Is Associated with Aggressive Behaviour of Human Clear-cell Renal Cell Carcinoma and Poor Patient Survival. P. DU, L. YE, Y. YANG, W.G. JIANG (Beijing, P.R. China; Cardiff, UK) ................................................................................................................................. 6515

N-(2-Amino-5-chlorobenzoyl) benzamidoxime Derivatives Inhibit Human Leukemia Cell Growth. Y. NAGAHARA, K. NAGAHARA (Saitama; Tokyo, Japan) .............................................................................................................. 6521

Gefitinib Inhibits Sodium Phosphate Co-transporter III Isoform 1 in a Model of Human Malignant Glioma. C. PUECH, N. PREVOT, N. PEREK (Saint-Etienne, France) ............................................................................................................. 6527

Impact of STAT3 Inhibition on Survival of Osteosarcoma Cell Lines. X. WANG, D. GOLDSTEIN, P.J. CROWE, J.-L. YANG (Randwick, Australia) .......................................................................................................................... 6537
Blue Light Activates Phase 2 Response Proteins and Slows Growth of A431 Epidermoid Carcinoma Xenografts. A.D. PATEL, S. ROTENBERG, R.L.W. MESSER, J.C. WATAHA, K.U.E. OGBUREKE, V.V. MCCLoud, P. LOCKWOOD, S. HSU, J.B. LEWIS (Augusta, GA; Columbus, OH; Seattle, WA; Houston, TX; Pomona, CA, USA) ................................................................................................................................. 6305

Cancer Resistance as an Acquired and Inheritable Trait. J. KOCH, J. HAU, H. ELVANG JENSEN, K. RIENECK (Copenhagen; Frederiksberg, Denmark) ...................................................................................... 6315

Effect of Withania somnifera Root Extract on Spontaneous Estrogen Receptor-negative Mammary Cancer in MMTV/Neu Mice. K.F. KHAZAL, D.L. HILL, C.J. GRUBBS (Tuskegee; Birmingham, AL, USA) .......... 6327

Magnolol Affects Expression of IGF-1 and Associated Binding Proteins in Human Prostate Cancer Cells In Vitro. B.T. McKEOWN, R.A.R. HURTA (Charlottetown, PE, Canada) ........................................................................................................ 6333

Cyclopamine Decreased the Expression of Sonic Hedgehog and its Downstream Genes in Colon Cancer Stem Cells. B.-E. BATSAIKHAN, K. YOSHIKAWA, N. KURITA, T. IWATA, C. TAKASU, H. KASHIHARA, M. SHIMADA (Tokushima, Japan) ......................................................................................... 6339

Transcriptional Targeting of Human Liver Carboxylesterase (hCE1m6) and Simultaneous Expression of Anti-BCRP shRNA Enhances Sensitivity of Breast Cancer Cells to CPT-11. M.N. MISHRA, K.K. VANGARA, S. PALAKURTHI (Kingsville, TX, USA) ................................................................................................................. 6345


Differential Impact of Tumor-infiltrating Immune Cells on Basal and Luminal Cells: Implications for Tumor Invasion and Metastasis. G. SONG, H. HSIAO, J.L. WANG, C. MANNION, A. STOJADINOVIC, I. AVITAL, S.W. FU, J. MASON, W. CHEN, A. JEWETT, H. LI, Y.-G. MAN (Beijing, P. R. China; Taichung; Changhua, Taiwan, ROC; New York, NY; Hackensack, NJ; Richmond, VA; Washington, DC; Baltimore, MD; Los Angeles, CA, USA) ..................................................................................................................... 6363


Nuclear Expression of Chemokine Receptor CXCR4 Indicates Poorer Prognosis in Gastric Cancer. T. MASUDA, Y. NAKASHIMA, K. ANDO, K. YOSHINAGA, H. SAEKI, E. OKI, M. MORITA, Y. ODA, Y. MAEHARA (Fukuoka, Japan) ........................................................................................................................... 6397


Sorafenib Induces Ferroptosis in Human Cancer Cell Lines Originating from Different Solid Tumors. E. LACHAIER, C. LOUANDRE, C. GODIN, Z. SAIDAK, M. BAERT, M. DIOUF, B. CHAUFFERT, A. GALMICHE (Amiens, France) .................................................................................................................. 6417

Contents continued on the preceding page